研究者詳細 - 佐々木　泰史

Misc - 佐々木　泰史

分割表示 360 件中 1 - 20 件目／全件表示 >>

胃底線ポリポーシスを背景とした胃腺窩上皮癌

足立靖, 見田裕章, 岩田徳和, 佐々木泰史, 安達靖代, 吉田幸成, 遠藤高夫, 石井良文, 後藤啓

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 ) 62回 P29 - 6 2024年10月

内視鏡的切除により診断できた皮膚様食道扁平上皮癌

足立靖, 菊地剛史, 後藤啓, 吉田幸成, 石井良文, 高橋宏明, 佐々木泰史, 仲瀬裕志, 遠藤高夫

日本消化管学会雑誌 ( (一社)日本消化管学会 ) 8 ( Suppl. ) 360 - 360 2024年01月

神経内分泌癌を混在した胃腺癌の肝転移再発例

足立靖, 足立靖, 見田裕章, 佐々木泰史, 吉田幸成, 遠藤高夫, 石井良文, 西田靖仙, 奥田博介, 高橋宏明, 後藤啓

日本がん転移学会学術集会・総会プログラム抄録集 33rd 2024年

J-GLOBAL

RAS野生型進行大腸癌に対する抗EGFR抗体治療におけるDroplet Digital PCRを用いた血中循環腫瘍DNAのモニタリング前向き観察研究

高橋直樹, 中村慶史, 木藤陽介, 久保田英嗣, 朝山雅子, 粂川陽祐, 原浩樹, 松島知広, 辻国広, 片岡洋望, 津矢田明泰, 佐々木泰史, 井戸川雅史, 時野隆至, 澤田武

大腸癌研究会プログラム・抄録集 101st 2024年

J-GLOBAL

症例報告からPrecision Medicineへ-第1部- 悪性貧血を伴う自己免疫性胃炎における胃癌と食道癌の同時発生(Simultaneous cancers of the stomach and esophagus in autoimmune gastritis with pernicious anemia)

足立靖, 久保俊之, 佐々木泰史, 安達靖代, 吉田幸成, 遠藤高夫, 石井良文, 高橋宏明, 後藤啓

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 ) 61回 ICCJ1 - 3 2023年10月

血清SOD活性と大腸癌罹患リスク

足立靖, 野島正寛, 森満, 久保俊之, 山野泰穂, 佐々木泰史, 仲瀬裕志, 遠藤高夫, 林櫻松, 若井建志, 玉腰暁子

日本癌学会総会記事 ( (一社)日本癌学会 ) 87 102455 - 102455 2023年09月 [ 国際誌 ]

BACKGROUND: Superoxide dismutase (SOD) is an antioxidant enzyme that degrades superoxide, a major causative factor in carcinogenesis. We assessed associations between serum SOD activities and incidence of colorectal carcinoma (CRC) in a case-control study nested in the Japan Collaborative Cohort (JACC) study. METHODS: At baseline, 39,242 subjects donated serum samples. Participants diagnosed with CRC during follow-up were regarded as cases. Odds ratios (ORs) for CRC incidence associated with SOD were evaluated with conditional logistic regression models. In the current study, 176 cases and 524 controls were analyzed. RESULTS: For the overall cohort, a decreasing trend in risk of CRC with increasing SOD was observed (P for trend=0.054) and the fourth quartile of SOD level showed the lowest risk compared to the first (OR=0.52, 95% confidence interval [CI]=0.29-0.93). This was significant in men (P for trend=0.001), with the fourth quartile of SOD level showing the lowest risk compared to the first (OR, 0.23; 95%CI, 0.09-0.60). It was also exclusively observed for rectal cancer and left-sided CRC (P for trend, 0.037 and 0.020, respectively), with the fourth quartile again showing the lowest risk compared to the first (OR, 0.28 and 0.38; 95%CI, 0.09-0.84 and 0.16-0.91, respectively). Limiting subjects to those followed-up over 2 years, all trends remained unchanged. CONCLUSIONS: Our findings suggest that serum SOD activity correlates inversely with risk of CRC, particularly in men and individuals with rectal cancer/left-sided CRC.

DOI PubMed

血清可溶性Fas値と肝臓癌罹患リスク(Serum soluble Fas levels and incidence of liver cancer)

足立靖, 野島正寛, 森満, 久保俊之, 阿久津典之, 佐々木泰史, 仲瀬裕志, 遠藤高夫, 林櫻松, 若井建志, 玉腰暁子

日本癌学会総会記事 ( (一社)日本癌学会 ) 82回 125 - 125 2023年09月

Prospective observational study of monitoring gene alterations in plasma cell-free DNA using droplet digital PCR system during anti-EGFR antibody treatment in patients with RAS wild-type advanced colorectal cancer.

Naoki Takahashi, Keishi Nakamura, Yosuke Kito, Eiji Kubota, Masako Asayama, Yosuke Kumekawa, Hiroki Hara, Tomohiro Matsushima, Kunihiro Tsuji, Hiromi Kataoka, Akihiro Tsuyada, Yasushi Sasaki, Masashi Idogawa, Takashi Tokino, Takeshi Sawada

Journal of Clinical Oncology ( American Society of Clinical Oncology (ASCO) ) 41 ( 4_suppl ) 172 - 172 2023年02月

研究発表ペーパー・要旨（国際会議）

172 Background: Anti-EGFR antibody is recommended as one of the standard treatments in patients with RAS wild-type advanced colorectal cancer (CRC). Few reports have evaluated low-frequency subclones of alterations in EGFR signaling pathway genes in plasma cell-free DNA (cfDNA) during anti-EGFR treatment in prospective cohort of advanced CRC patients. Methods: Key inclusion criteria of this study was as follows: 20 years old and over, performance status 0 to 2, metastatic or recurrent CRC (adenocarcinoma), RAS wild-type CRC diagnosed by PCR-rSSO using tumor tissue, no prior use of anti-EGFR antibody. Plasma samples were prospectively collected at pre-treatment, at 4, 10 weeks, every 10 weeks thereafter, and at the end of the anti-EGFR treatment. With QX200 Droplet Digital PCR platform, we analyzed hotspot mutations of KRAS, NRAS, BRAF, and PIK3CA and copy number (CN) variant of HER2 and MET using plasma samples of pre- and post-treatment as well as during treatment (limited to patients with any gene alterations at pre- and post-treatment). Results: Total 50 patients were registered in this study, but 3 patients were excluded because inclusion criteria were not met. Finally, 47 patients were included in full analysis set. In 15 patients (31.9%), genetic alterations including KRAS (G12G13: 10.1%, A59Q61: 2.2%), NRAS (G12G13: 2.2%, Q61: 2.1%), BRAF (V600: 6.4%) , PIK3CA (E545: 4.3%, H1047: 4.3%) , and HER2 (amplification: 6.5%) were detected in pre-treatment samples. Analysis of pre-treatment samples showed that response rates of patients with any gene alterations (N = 13) and that without any gene alterations (N = 29) were 30.8% and 58.6%, respectively (p = 0.095). When the cut-off of variant allele frequency (VAF) was set as 0.5% in patients with any gene mutations, the response rates for cases with VAF ≥0.5% (N = 6) and those with VAF < 0.5% (N = 7) were 0% and 57.1%, respectively (p = 0.049). Among 41 patients with detectable target lesions by CT scan, there was significant difference in percentage of best tumor shrinkage between patients with gene alterations and those without gene alterations (32.1% vs 10.5%, p = 0.037), when cut-off VAF of any gene mutations was set as 0.5% and cut-off CN of HER2 or MET was set as 4 at pre-treatment. Due to dynamics of each gene alteration in cfDNA during treatment, mutations of KRAS A59Q61, NRAS Q61, and MET amplification were characterized as acquired alterations which were newly detected after the administration of anti-EGFR antibodies. Conclusions: Our study demonstrated the clinical relevance of minor mutant subclones in EGFR signaling pathway genes in plasma for predicting response to anti-EGFR treatment. Although sample size of this study was small, preferable threshold for distinguishing responders from non-responders may be 0.5% as VAF of these gene mutations. Clinical trial information: 000034923 .

DOI

非乳頭部十二指腸腫瘍におけるERBB受容体ファミリーの解析と治療標的の探索

佐々木泰史, 澤田武, 中村慶史

金沢大学がん進展制御研究所がんの転移・薬剤耐性に関わる先導的共同研究拠点 2022 2023年

J-GLOBAL

悪性貧血を伴う自己免疫性胃炎における胃と食道の同時癌【JST・京大機械翻訳】|||

足立靖, 足立靖, 久保俊之, 久保俊之, 佐々木泰史, 安達靖代, 吉田幸成, 遠藤高夫, 石井良文, 高橋宏明, 後藤啓

日本癌治療学会学術集会(Web) ( (一社)日本癌治療学会 ) 61st ICCJ1 - 3 2023年

J-GLOBAL

口腔がんにおけるClaudin-1発現抑制分子機構の解明

丹下正一朗, 井戸川雅史, 川島秀器, 佐々木泰史, 時野隆至

日本分子生物学会年会プログラム・要旨集(Web) 46th 2023年